Monoclonal antibody 2G1 against Ebola virus glycoprotein (GP)2 subunit, and application of monoclonal antibody 2G1

A monoclonal antibody, Ebola virus technology, applied in the field of peptides, to achieve excellent broad-spectrum effects

Active Publication Date: 2020-05-12
ACADEMY OF MILITARY MEDICAL SCI
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, the first two ways have been confirmed by literature, and the third way is the speculation of some literature, and there is no direct evidence yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody 2G1 against Ebola virus glycoprotein (GP)2 subunit, and application of monoclonal antibody 2G1
  • Monoclonal antibody 2G1 against Ebola virus glycoprotein (GP)2 subunit, and application of monoclonal antibody 2G1
  • Monoclonal antibody 2G1 against Ebola virus glycoprotein (GP)2 subunit, and application of monoclonal antibody 2G1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Antibody Preparation

[0033] 1. Blood Sample Collection

[0034] After obtaining informed consent, 5 mL of blood samples were collected 28 days after the second immunization of the recombinant Ebola vaccine clinical trial subjects for subsequent experiments.

[0035] 2. FITC-labeled protein GPdM

[0036] Specific memory B cells need to be sorted by fluorescently labeled antigens. The method of FITC-labeled truncated antigen protein GPdM is as follows:

[0037] 1) Fluorescein Isothiocyanate_FITC (SIGMA, F4274) was dissolved in DMSO at a concentration of 20 mg / mL.

[0038] 2) Take 100 μL of GPdM (3.3 mg / mL), add buffer (pH9.6 carbonate buffer) to 400 μL.

[0039] 3) Add 8 μL FITC to the GPdM solution, and incubate at 4° C. in the dark for 3 hours.

[0040] 4) Use a 50kD centrifugal concentrator tube to replace the solution with PBS until the filtrate is transparent and colorless. Wrap the labeled protein in tinfoil and store at 4°C until use.

[0041] 3....

Embodiment 2

[0122] Example 2.ELISA detection of antibody binding activity

[0123] 1) The day before the experiment, 96-well enzyme-linked plates were coated with 1 μg / mL of EBOV GP, BDBV GP, SUDV GP and RESTV GP, 100 μL per well. Put the coated ELISA plate in a humid box overnight at 4°C.

[0124] 2) Wash 5 times with a plate washer on the day of the experiment.

[0125] 3) Add 100 μL of blocking solution to each well and let stand at room temperature for 1 hour.

[0126] 4) Wash the plates 5 times in a plate washer.

[0127] 5) Add 150 μL of 2G1 monoclonal antibody at a concentration of 10 μg / mL to the first well, and add 100 μL of diluent to the remaining wells. Aspirate 50 μL from the first well and add to the second well, and so on, dilute the solution in a 1:3 gradient to a final volume of 100 μL in each well. Let stand at room temperature for 1 hour.

[0128] 6) Wash the plates 5 times in a plate washer.

[0129] 7) Dilute the HPR-labeled goat anti-human IgG secondary antibod...

Embodiment 3

[0134] Embodiment 3. Pseudovirus neutralization experiment evaluates 2G1 neutralization activity

[0135] EBOV, BDBV, and SUDV pseudoviruses packaging the HIV backbone were evaluated in vitro for neutralizing activity of 2G1. The evaluation method is as follows:

[0136] 1) Dilute the 2G1 monoclonal antibody with DMEM medium, add 75 μL of antibody diluent with a concentration of 100 μg / mL to the first well of a 96-well cell culture plate, and add 50 μL of DMEM medium to the remaining wells.

[0137] 2) Pipette 25 μL of liquid from the first well into the second well, mix well, and so on, dilute at a ratio of 1:3, and the final volume of each well is 50 μL.

[0138] 3) Dilute the pseudovirus 1:5 with DMEM medium (control the fluorescein reading in the control well between 20,000 and 100,000), add to each antibody well, 50 μL per well. Mix well and incubate at 37°C for 1h.

[0139] 4) 293T cell count, 2×10 5 cells / mL, add 100 μL to each well.

[0140] 5) Place the 96-well c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a monoclonal antibody 2G1 against an Ebola virus glycoprotein (GP)2 subunit. The antibody has a unique CDR region, shows excellent broad-spectrum properties in antigen bindingability, and has good binding activity with EBOVGP, BDBV GP, SUDV GP and RESTV GP, and the binding is stable and not affected by the low pH environment of late endosomes, so that a basis for the antibody playing a neutralizing role is provided. Compared with a control antibody, the 2G1 can effectively neutralize EBOV, BDBV and SUDV pseudo-viruses in vitro; and the neutralizing activity of the antibody provided by the invention is increased with the increase of the antibody concentration, and the antibody can realize nearly 100% protection against three Ebola pseudo-viruses, namely EBOV, BDBV and SUDV at a concentration of 1 [mu]g / mL. The antibody provided by the invention also has a unique action site which is different from an action site of a monoclonal antibody against the Ebola virus envelope glycoprotein in the prior art, so that the result suggests that the antibody provided by the invention has the potential of forming a cocktail combination therapy with other neutralizing antibodies.

Description

technical field [0001] The invention discloses an antibody and belongs to the technical field of polypeptides. Background technique [0002] Ebola virus (EBOV) can cause acute severe hemorrhagic fever in humans and non-human primates. It is one of the viruses with the highest fatality rate found so far, with a fatality rate as high as 90%. It can be transmitted directly through contact , highly contagious and lethal. The glycoprotein (Glycoprotein, GP) spike on the surface of the Ebola virus envelope almost mediates all steps of the virus entering the cell, so Ebola GP is an important target of virus neutralizing antibodies. The Ebola virus GP gene is processed into two proteins, one is secreted non-structural GP (secreted glycoprotein, sGP); the other is structural GP. Ebola GP is first synthesized as a polypeptide, and then cleaved by Furin enzyme into GP1 (amino acids 1-501) and GP2 (amino acids 502-676) subunits. The two subunits are connected by disulfide bonds to for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N5/10A61K39/42A61P31/14
CPCC07K16/10C12N5/0636A61P31/14C07K2317/565C07K2317/92C07K2317/76C12N2510/00A61P31/00A61K2039/505C07K2317/94
Inventor 陈薇于长明范鹏飞迟象阳张冠英侯利华房婷吴诗坡陈旖陈郑珊王美荣刘渝娇
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap